Evidence map›Paper›PMID 33946076›Full record

ArticleJournal of innate immunity2021

The Efficacy of Posttreatment with Synthetic C-Reactive Protein in Murine Bacterial Peritonitis via Activation of FcγRI-Expressing Kupffer Cells.

Manabu Kinoshita, Seigo Ito, Takuya Ishikiriyama, Kumiko Sekiguchi, Ryota Yamaguchi, Ryoichi Tsuruhara, Akihisa Matsuda, Kazuki Koiwa, Masahiro Nakashima, Hiroyuki Nakashima and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of innate immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. C-Reactive Protein Is Not the Driver Factor in Ulcerative Colitis.Gastroenterology research and practice · 2024
    Article
  3. Review
  4. C-Reactive Protein: More than a Biomarker.Journal of innate immunity · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Manabu KinoshitaDepartment of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Seigo ItoDepartment of Nephrology and Endocrinology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Takuya IshikiriyamaDepartment of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Kumiko SekiguchiDepartment of Surgery, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba, Japan.
Ryota YamaguchiMedical Student, National Defense Medical College, Tokorozawa, Saitama, Japan.
Ryoichi TsuruharaMedical Student, National Defense Medical College, Tokorozawa, Saitama, Japan.
Akihisa MatsudaDepartment of Surgery, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba, Japan.
Kazuki KoiwaDepartment of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Masahiro NakashimaDepartment of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Hiroyuki NakashimaDepartment of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Masao MiyashitaDepartment of Surgery, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba, Japan.
Shuhji SekiDepartment of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Saitama, Japan.
National Defense Medical College · JPChiba Hokusou Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pretreatment with synthetic C-reactive protein (CRP), a functional CRP peptide, has the potential to augment macrophage phagocytosis by bacterial challenge. However, the posttreatment is clinically ideal. We investigated the efficacy of posttreatment with synthetic CRP on murine cecal ligation and puncture (CLP), focusing on liver macrophages. Mice received CLP, and 1 h later, synthetic CRP or saline was intraperitoneally administered. Posttreatment with synthetic CRP increased the murine survival after CLP. It reduced viable bacterial counts in the liver 24 h after CLP with an increase in the number of Kupffer cells but not monocyte-derived liver macrophages. Posttreatment with synthetic CRP increased the phagolytic activity of Kupffer cells against Escherichia coli (E. coli) as well as capsulated Klebsiella pneumoniae at 3 h after CLP. Synthetic CRP therapy augmented TNF production by E. coli-phagocytosing Kupffer cells, resulting in an increase in tissue TNF levels in the liver at 24 h. Kupffer cells substantially expressed FcγRI, which is a ligand of CRP, and their FcγRI expression was further increased after CLP. In contrast, synthetic CRP therapy affected neither the phagocytic function of monocyte-derived liver macrophages (showing a weak FcγRI expression) nor their TNF production. Depletion of Kupffer cells in mice inhibited these beneficial effects of synthetic CRP in CLP mice. Conclusion: Posttreatment with synthetic CRP effectively improves murine bacterial peritonitis via the activation of phagocytosis of FcγRI-expressing Kupffer cells.

Indexed as

PeritonitisSepsisAnimalsC-Reactive ProteinEscherichia coliKupffer CellsMiceReceptors, IgGC-Reactive ProteinReceptors, IgGCecal ligation and punctureLiver macrophagesPhagolysosomal activity

Identifiers

PMID33946076
PMCPMC8460980
OpenAlexW3159587258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.